A case of postirradiation vaginal angiosarcoma treated with recombinant interleukin-2 therapy.
Angiosarcoma of the vagina is an extremely rare neoplasm and is characterized by frequent recurrence and early metastatic spread. Although previous reports emphasized the poor prognosis of this disease, effective treatment strategies have not been adequately stated. We report a case of angiosarcoma of the vagina, in which the diagnosis was made 9 years after intrapelvic irradiation, and recombinant interleukin-2 (rIL-2) therapy could be effective to suppress the development of distant metastasis. We recommend rIL-2 therapy in combination with irradiation as a palliative therapeutic option for vaginal angiosarcoma when the tumor is inoperable or the patient refuses to undergo surgery. Although vaginal angiosarcoma is an extremely rare condition, its possibility should be borne in mind when finding a vaginal mass in a previously irradiated patient.
Takeuchi
K
K
Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan. kyousuket@dolphin.ocn.ne.jp
Deguchi
M
M
Hamana
S
S
Motoyama
S
S
Kitazawa
S
S
Maruo
T
T
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001918:Brachytherapy; D004407:Dysgerminoma / Q000628:therapy; D017809:Fatal Outcome; D005260:Female; D013509:Gynecologic Surgical Procedures; D006394:Hemangiosarcoma / Q000556:secondary / Q000628:therapy*; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy*; D008875:Middle Aged; D009381:Neoplasms, Radiation-Induced / Q000209:etiology*; D010051:Ovarian Neoplasms / Q000628:therapy; D011878:Radiotherapy / Q000009:adverse effects*; D016896:Treatment Outcome; D014625:Vaginal Neoplasms / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents; D007376:Interleukin-2